{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T17:02:34Z","timestamp":1794416554042,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","award":["20-181"],"award-info":[{"award-number":["20-181"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","award":["18-181"],"award-info":[{"award-number":["18-181"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la Ricerca sul Cancro ETS","doi-asserted-by":"publisher","award":["IG 2024"],"award-info":[{"award-number":["IG 2024"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la Ricerca sul Cancro ETS","doi-asserted-by":"publisher","award":["IG 2018 \\u2013 21787"],"award-info":[{"award-number":["IG 2018 \\u2013 21787"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annonc.2026.05.694","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:16:19Z","timestamp":1779203779000},"page":"1278-1292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-2763","authenticated-orcid":false,"given":"M.","family":"Dugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-211X","authenticated-orcid":false,"given":"C.-S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0283-8176","authenticated-orcid":false,"given":"D.","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7773-5994","authenticated-orcid":false,"given":"B.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7143-9091","authenticated-orcid":false,"given":"C.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ant\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sevillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-421X","authenticated-orcid":false,"given":"B.","family":"Galbardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Semiglazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"L.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-3143","authenticated-orcid":false,"given":"G.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":false,"given":"L.","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Callari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"G.","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2026.05.694_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib2","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1095839","article-title":"Triple negative breast cancer: immunogenicity, tumor microenvironment, and immunotherapy","volume":"13","author":"Loizides","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.annonc.2026.05.694_bib4","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes","volume":"26","author":"Ali","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/PD-L1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2026.05.694_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.annonc.2026.05.694_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.05.694_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2026.05.694_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.008","article-title":"LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: updated EFS results from the phase III KEYNOTE-522 study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz095.003","article-title":"Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial","volume":"30","author":"Loi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib14","doi-asserted-by":"crossref","first-page":"S1145","DOI":"10.1016\/j.annonc.2020.08.2241","article-title":"LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial","volume":"31","author":"Bianchini","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib15","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-20-3113","article-title":"Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer","volume":"27","author":"Sinn","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2022.40.16_suppl.514","article-title":"The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2","volume":"40","author":"Mittempergher","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.annonc.2026.05.694_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.05.694_bib18","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.3390\/cancers13194839","article-title":"A novel immunomodulatory 27-gene signature to predict response to neoadjuvant immunochemotherapy for primary triple-negative breast cancer","volume":"13","author":"Iwase","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2026.05.694_bib19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2020.05.015","article-title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","volume":"31","author":"Karn","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib20","article-title":"Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer","volume":"5","author":"Denkert","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.annonc.2026.05.694_bib21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2026.05.694_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.05.694_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P2-07-12","article-title":"Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial","volume":"82","author":"Dugo","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.annonc.2026.05.694_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.annonc.2026.05.694_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Systems"},{"key":"10.1016\/j.annonc.2026.05.694_bib28","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","article-title":"Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods","volume":"79","author":"Jim\u00e9nez-S\u00e1nchez","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","article-title":"Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy","volume":"35","author":"Yang","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.annonc.2026.05.694_bib30","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btae440","article-title":"InstaPrism: an R package for fast implementation of BayesPrism","volume":"40","author":"Hu","year":"2024","journal-title":"Bioinformatics"},{"key":"10.1016\/j.annonc.2026.05.694_bib32","series-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","first-page":"785","article-title":"XGBoost: a scalable tree boosting system","author":"Chen","year":"2016"},{"key":"10.1016\/j.annonc.2026.05.694_bib33","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1007\/s11010-025-05305-z","article-title":"Ferroptosis in TNBC: interplay with tumor-infiltrating immune cells and therapeutic implications","volume":"480","author":"Hu","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.annonc.2026.05.694_bib34","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1158\/1078-0432.CCR-24-0149","article-title":"The immune-related 27-gene signature determines response to neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer","volume":"30","author":"Dugo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib35","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-21-3215","article-title":"Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in basal-like triple-negative breast cancer","volume":"28","author":"Blenman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaoncol.2020.7310","article-title":"Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the BrighTNess phase 3 randomized clinical trial","volume":"7","author":"Filho","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib37","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.annonc.2026.05.694_bib38","first-page":"3055","article-title":"Cancer-associated fibroblast regulation of tumor neo-angiogenesis as a therapeutic target in cancer","volume":"17","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annonc.2026.05.694_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","article-title":"Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2026.05.694_bib40","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","article-title":"Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer","volume":"12","author":"Anurag","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.05.694_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","article-title":"Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets","volume":"33","author":"Gong","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.annonc.2026.05.694_bib42","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.apsb.2022.10.027","article-title":"The impact of lipids on the cancer\u2013immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.annonc.2026.05.694_bib43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.05.694_bib44","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-PD2-07","article-title":"Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)\u2014results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial","volume":"79","author":"Loibl","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib46","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-PD10-09","article-title":"Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment","volume":"82","author":"Callari","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib47","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1158\/0008-5472.CAN-22-3471","article-title":"GTP cyclohydrolase drives breast cancer development and promotes EMT in an Enzyme-independent manner","volume":"83","author":"Wang","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13058-019-1159-3","article-title":"On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"21","author":"Bownes","year":"2019","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annonc.2026.05.694_bib49","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.2014.57.8963","article-title":"Accurate prediction and validation of response to endocrine therapy in breast cancer","volume":"33","author":"Turnbull","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.694_bib50","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.05.694_bib51","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/s41591-024-03266-2","article-title":"Datopotamab\u2013deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Khoury","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.05.694_bib52","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","article-title":"Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426008781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:49:37Z","timestamp":1787428177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426008781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0923753426008781"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.694","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}